Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.32 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.32 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1299137 | 0.87 | CSNK1D (0.30) | CSNK1DCSNK1E | |
| SCHEMBL1298491 | 0.79 | JAK2 (0.38) | KDM4EALDH1A1HPGDCSNK1DCSNK1E | |
| SCHEMBL1298977 | 0.79 | GPR139 (0.31) | KDM4EALDH1A1HPGDCSNK1DCSNK1E | |
| SCHEMBL1298537 | 0.79 | ALDH1A1 (0.35) | KDM4EALDH1A1HPGDCSNK1DCSNK1E | |
| SCHEMBL1298213 | 0.78 | CSNK1D (0.31) | CSNK1DCSNK1E | |
| SCHEMBL1298741 | 0.77 | CSNK1D (0.32) | CSNK1DCSNK1E | |
| SCHEMBL1299071 | 0.76 | CSNK1D (0.31) | CSNK1DCSNK1E | |
| SCHEMBL1298181 | 0.72 | CSNK1D (0.39) | KDM4EALDH1A1HPGDCSNK1DCSNK1E | |
| SCHEMBL3249781 | 0.71 | JAK2 (0.46) | — | |
| SCHEMBL1297982 | 0.71 | JAK2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2011-11-03 | — | — | US | claimed |
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | KDM4E 1049/4885ALDH1A1 4263/4885HPGD 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.